ESMO 2021 Solid Tumor – Ian Chau

Ian Chau depicts the most interesting trial results in the field of esophageal cancer at the ESMO 2021 congress, gives an outlook on personalized approaches in the setting of esophageal squamous-cell carcinoma with regard to biomarkers for checkpoint inhibitors as well as potential further improvements of the prognosis of patients with esophageal cancer.

Here is the full ESMO 2021 Solid Tumors report.